IMC-2032 is under clinical development by ImmuneCyte and currently in Phase I for Premature Ageing. According to GlobalData, Phase I drugs for Premature Ageing does not have sufficient historical data ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
There's not enough human-generated data to keep AI models improving at the same rate. 2025 will put a new solution to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback